Mylan/Biocon Running Out Of Time To Get Insulin Approved Before US Transition

 
• By Michael Cipriano
Time-flies
The clock continues to tick for Mylan and Biocon's insulin glargine NDA following another CRL.

More from Biosimilars

More from Biosimilars & Generics